1. Show article details.

    Cibus Appoints Co-Founder Rory Riggs, as Chief Executive Officer

    Business Wire – 9:00 AM ET 10/07/2021

    Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. “Since our founding, Rory has been an important strategic partner in the success of Cibus and we are pleased that he is deepening his involvement in the company’s growth as CEO,” said Dr. Beetham.

  2. Show article details.

    BRIEF-FibroGen Announces Positive Topline Results From Phase 2 Clinical Trial Of Roxadustat For The Treatment Of Chemotherapy Induced Anemia

    Reuters – 7:12 AM ET 08/25/2021

    FibroGen Inc (FGEN): * FIBROGEN ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF ROXADUSTAT FOR THE TREATMENT OF CHEMOTHERAPY INDUCED ANEMIA. * FibroGen Inc (FGEN) - ROXADUSTAT WAS GENERALLY WELL TOLERATED Source text for Eikon: Further company coverage:

  3. Show article details.

    FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

    GlobeNewswire – 7:00 AM ET 08/25/2021

    FibroGen, Inc. (FGEN) today announced positive topline results from WHITNEY, the Company’s Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of chemotherapy-induced anemia.

  4. Show article details.

    Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

    GlobeNewswire – 7:35 PM ET 08/19/2021

    Astellas Pharma Inc. and FibroGen, Inc. (FGEN) today announced that the European Commission has approved EVRENZO™  for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease.

  5. Show article details.

    BRIEF-Astellas Receives European Commission Approval For First-In-Class Evrenzo (Roxadustat) For Adult Patients With Symptomatic Anemia Of Chronic Kidney Disease

    Reuters – 7:34 PM ET 08/19/2021

    Astellas Pharma Inc (ALPMF): * ASTELLAS RECEIVES EUROPEAN COMMISSION APPROVAL FOR FIRST-IN-CLASS EVRENZO FOR ADULT PATIENTS WITH SYMPTOMATIC ANEMIA OF CHRONIC KIDNEY DISEASE. * EC APPROVAL OF ROXADUSTAT TRIGGERS A MILESTONE PAYMENT OF $120 MILLION BY CO TO FIBROGEN. * FIBROGEN WILL ALSO RECEIVE ROYALTIES BASED UPON EUROPEAN NET SALES Source text for Eikon: Further company coverage:

  6. Show article details.

    Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

    PR Newswire – 7:30 PM ET 08/19/2021

    TOKYO  Astellas Pharma Inc. (ALPMF) and FibroGen, Inc. (FGEN) today announced that the European Commission has approved EVRENZO™ for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease.

  7. Show article details.

    BRIEF-Fibrogen Announces Retirement Of Pat Cotroneo And Appointment Of Juan Graham As CFO

    Reuters – 7:19 AM ET 08/16/2021

    FibroGen Inc (FGEN): * FIBROGEN ANNOUNCES RETIREMENT OF PAT COTRONEO AND APPOINTMENT OF JUAN GRAHAM AS CHIEF FINANCIAL OFFICER. * FibroGen Inc (FGEN) - GRAHAM WAS MOST RECENTLY GLOBAL CHIEF FINANCIAL OFFICER / VICE PRESIDENT FINANCE SUPPLY CHAIN AT JOHNSON & JOHNSON INC. * FibroGen Inc (FGEN) - GRAHAM WILL BECOME CHIEF FINANCIAL OFFICER EFFECTIVE SEPTEMBER 7, 2021 Source text for Eikon: Further company coverage:

  8. Show article details.

    FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer

    GlobeNewswire – 7:00 AM ET 08/16/2021

    FibroGen, Inc. (FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. “On behalf of the board, shareholders, and our employees, I want to thank Pat for his contributions as Chief Financial Officer and dedicated service over the past 21 years,” said Enrique Conterno, Chief Executive Officer, FibroGen.

  9. Show article details.

    AstraZeneca Says US FDA Calls for Extra Clinical Trial on Safety of Roxadustat

    DJ Business News – 10:03 AM ET 08/11/2021

    AstraZeneca PLC (AZN) said Wednesday that the U.S. Food and Drug Administration has asked for an extra clinical trial of roxadustat for the treatment of anemia of chronic kidney disease before it can approve the company's new drug application. The pharmaceutical giant said that it is working with its partner FibroGen Inc. (FGEN) to evaluate the next steps.

  10. Show article details.

    BRIEF-FibroGen Receives Complete Response Letter From The FDA For Roxadustat For Anemia Of Chronic Kidney Disease

    Reuters – 7:11 AM ET 08/11/2021

    FibroGen Inc (FGEN): * FIBROGEN RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR ROXADUSTAT FOR ANEMIA OF CHRONIC KIDNEY DISEASE. * FibroGen Inc (FGEN) - COMPLETE RESPONSE LETTER INDICATES FDA WILL NOT APPROVE ROXADUSTAT NDA IN ITS PRESENT FORM. * FibroGen Inc (FGEN) - FDA HAS REQUESTED ADDITIONAL CLINICAL STUDY OF ROXADUSTAT BE CONDUCTED, PRIOR TO RESUBMISSION Source text for Eikon: Further company coverage:

  11. Show article details.

    U.S. FDA declines to approve FibroGen's anemia drug

    Reuters – 7:05 AM ET 08/11/2021

    FibroGen Inc (FGEN) said said on Wednesday that the U.S. Food and Drug Administration has declined to approve its treatment for anemia, citing the need for an additional clinical study.

  12. Show article details.

    FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease

    GlobeNewswire – 7:00 AM ET 08/11/2021

    FibroGen (FGEN), Inc.  today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for roxadustat for the treatment of anemia of chronic kidney disease. The letter indicates the FDA will not approve the roxadustat NDA in its present form and has requested additional clinical study of roxadustat be conducted, prior to resubmission.

  13. Show article details.

    BRIEF-Fibrogen Reports Second Quarter 2021 Financial Results

    Reuters – 4:10 PM ET 08/09/2021

    FibroGen Inc (FGEN): * FIBROGEN REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS. * Q2 LOSS PER SHARE $1.45. * Q2 REVENUE $24.4 MILLION. * Q2 REVENUE ESTIMATE $69.1 MILLION -- REFINITIV IBES DATA. * Q2 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  14. Show article details.

    FibroGen Reports Second Quarter 2021 Financial Results

    GlobeNewswire – 4:01 PM ET 08/09/2021

    • Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis.

  15. Show article details.

    FibroGen to Report Second Quarter 2021 Financial Results

    GlobeNewswire – 7:00 AM ET 07/29/2021

    FibroGen, Inc. (FGEN) will announce its second quarter 2021 financial results on Monday, August 9 after the market close. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen (FGEN) website at https://fibrogen.gcs-web.com/events-and-presentations/events. Dial-In InformationLive: 658-9081Live: 563-8732Confirmation number: 4951789.

  16. Show article details.

    Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform

    GlobeNewswire – 7:00 AM ET 07/19/2021

    SUZHOU, China and SAN FRANCISCO, July 19, 2021 -- Eluminex Biosciences Limited, an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, announced today that it has exclusively licensed global rights for the development and commercialization of an investigational biosynthetic cornea derived from recombinant ...

  17. Show article details.

    FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

    GlobeNewswire – 6:26 PM ET 07/15/2021

    FibroGen, Inc. (FGEN) today announced that the U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia due to chronic kidney disease in adult patients.

  18. Show article details.

    FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer

    GlobeNewswire – 7:00 AM ET 07/12/2021

    FibroGen, Inc. (FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen’s research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience. “Great science and innovation are the backbone of FibroGen (FGEN) and what enable us to develop transformational medicines for patients.

  19. Show article details.

    Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

    GlobeNewswire – 9:15 AM ET 06/25/2021

    Astellas Pharma Inc. and FibroGen, Inc. (FGEN) today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion relating to the use of roxadustat for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease.1 CKD impacts one in 10 people globally, of whom one in five are affected by anemia.2, 3 Ane...

  20. Show article details.

    FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease

    GlobeNewswire – 7:00 AM ET 06/17/2021

    SAN FRANCISCO and CAMBRIDGE, Mass., June 17, 2021 -- FibroGen, Inc. (FGEN) and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science announced a partnership covering three HiFiBiO programs.

Page:

Today's and Upcoming Events

  • Nov
    02

    FGEN to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    09

    FGEN announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.